Deverra Therapeutics develops allogeneic universal donor cellular immunotherapies using healthy donor umbilical cord blood cells, eliminating the need for donor-patient matching. Their scalable manufacturing process provides ready-made therapies for immediate use, addressing the accessibility and cost-effectiveness of treatment options for patients with various cancers.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current allogeneic cell therapies require donor-patient matching, which can be a barrier to access and timely treatment. Existing therapies may also have limitations in scalability and cost-effectiveness, hindering widespread availability for patients with cancer and other critical diseases.
Solution
Deverra Therapeutics is developing off-the-shelf, allogeneic cell therapies derived from healthy donor umbilical cord blood, eliminating the need for donor-patient matching. Their platform technology is designed to generate various cell types, creating a diverse pipeline of cell therapies for multiple indications. The company's scalable manufacturing and cryopreservation process enables the delivery of ready-made therapies for immediate, on-demand use. Deverra's lead product, Dilanubicel, is being developed as a non-engrafting adjuvant cell therapy with chemotherapy to enhance remission rates and improve overall survival in AML patients.
Target Audience
The primary target audience includes patients with AML and other cancers, as well as healthcare providers seeking accessible and cost-effective cell therapy options.
Features
- Dilanubicel: A stem and progenitor cell therapy in clinical stage for newly diagnosed AML patients.
- Unmodified NK cells and myeloid cells: Engineered to fight cancer and boost immunity against viral infections.
- Modified NK and myeloid cells: Designed to target blood cancers and solid tumors, used alone or in combination with other cell therapy products.
- Scalable manufacturing process: Allows for the generation of hundreds of doses per manufacturing run.
- Cryopreservation SOP: Enables off-the-shelf availability and on-demand use.
- No genetic modifications of the starting material required for NK cell generation.
- Non-viral gene delivery systems: Investigated for modified immune effector cells.